New Data Highlight Artera's MMAI Consistency Across Diverse Patient Populations at ASTRO 2026

Five abstracts spanning global patient cohorts and U.S. cooperative trials reinforce the prognostic and predictive power of Artera's platform in prostate cancer

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will be featured in new data presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Collectively, these studies expand the evidence supporting MMAI's potential to deliver consistent, biologically meaningful insights across diverse patient populations and clinical settings. The findings carry implications for more personalized prostate cancer treatment. Details of the abstracts are below.

“We believe the future of cancer care is one where the patient’s unique biology and risk increasingly inform personalized treatment decisions,” said Andre Esteva, CEO and Co-founder of Artera. “These findings demonstrate the potential of Artera's platform to deliver on this vision by providing consistent, data-backed insights across diverse populations, helping clinicians better tackle some longstanding questions in medicine today."

Key Presentations at ASTRO 2026

Beyond NCCN: How a Prognostic and Predictive Multimodal AI Biomarker Drives ADT De-Escalation in Prostate Cancer

Quick Pitch: Actionable Biomarkers: Guiding Therapy Selection and De-escalation
Abstract Number: 1163
Date and Time: September 29, 5:20 PM ET, Room 205

New data from the GenesisCare-led ASTuTE Trial in Australia reveal how Artera's MMAI biomarker can help guide clinical decisions around Short-Term Androgen Deprivation Therapy (ST-ADT) for men with intermediate-risk prostate cancer. Leveraging MMAI to inform treatment discussions led many patients and clinicians to reconsider ST-ADT in both directions, avoiding the therapy when risk didn't warrant it, and pursuing it when the test indicated likely benefit. These findings continued to add to Artera’s cross-continental evidence base, supporting its MMAI’s potential to advance personalized treatment decisions.

Digital Pathology-Based Multimodal Artificial Intelligence Biomarker Validation in Patients with High and Very High Risk Localized Prostate Cancer from the POP-RT Trial

Oral Presentation: Predicting Benefit and Toxicity: Biomarkers in Prostate Radiotherapy
Abstract Number: 313
Date and Time: September 29, 4:05 PM ET; Room 210

Data demonstrate the potential of Artera’s MMAI biomarker to help personalize radiation treatment for patients with high-risk localized prostate cancer. In a study of patients treated in India, whole-pelvis radiation was associated with a meaningful reduction in distant metastasis among patients with high MMAI risk, while those with intermediate MMAI risk did not derive a similar benefit. There are currently no validated biomarkers available to guide selection for whole-pelvis radiation. These findings suggest that Artera may help identify patients most likely to benefit from more extensive radiation treatment, supporting more personalized treatment decisions while potentially avoiding unnecessary radiation exposure. The study represents the first validation of Artera’s MMAI in a South Asian prostate cancer population, supporting continued investigation of its potential to inform radiation treatment decisions.

Benchmarking Multimodal AI-Predicted Metastasis and Prostate Cancer-Specific Mortality Risk Against STAR-CAP: A 20,000-Patient Commercial Experience

Poster Presentation: Genitourinary Cancer, Gynecological Cancer, and Health Care Access and Engagement
Abstract Number: 3379
Date and Time: September 29 at 2:15 PM ET; Exhibit Hall A

Findings reveal that risk estimates generated by Artera's MMAI biomarker for patients tested in a real-world commercial setting align with observed rates of distant metastasis and prostate cancer-specific mortality in STAR-CAP, a database of nearly 20,000 prostate cancer patients with long-term follow-up across a broad range of risk groups and treatment approaches. Across each NCCN risk group, MMAI-projected risks were comparable to observed rates in STAR-CAP, providing additional evidence that MMAI risk estimates reflect outcomes in a diverse prostate cancer population and are generalizable beyond the clinical trial populations in which the MMAI biomarker has been validated.

Cross-Continental Transcriptomic Evaluation of a Multimodal AI-Based Biomarker in Localized Prostate Cancer

Poster Presentation: Genitourinary Cancer, Gynecological Cancer, and Health Care Access and Engagement
Abstract Number: 3397
Date and Time: September 29 at 2:15 PM ET; Exhibit Hall A

Researchers determined that biological signals captured by Artera's MMAI biomarker are consistent across native African, African American, and European American patients with localized prostate cancer. Using transcriptomic analyses, researchers compared MMAI scores and gene expression patterns in ~90 patients across these three populations and found that higher MMAI scores were associated with similar gene expression patterns linked to more aggressive prostate cancer, including those tied to tumor growth and metastasis. The findings support the biological consistency and generalizability of MMAI across diverse, global patient populations.

Assessing MMAI Algorithmic Fairness within Racial and Age Subgroups In NRG/RTOG Post-Radical Prostatectomy Phase III Trials

Quick Pitch: Actionable Biomarkers: Guiding Therapy Selection and De-escalation
Abstract Number: 1165
Date and Time: September 29 at 5:30 PM ET; Room 205

The findings reinforce the fairness and generalizability of Artera's post-prostatectomy MMAI biomarker across diverse patient populations. African American men face a disproportionately worse prostate cancer prognosis and have historically been underrepresented in biomarker development. Researchers evaluated whether Artera’s MMAI performed consistently across racial and age subgroups using NRG/RTOG trial data. The biomarker’s prognostic accuracy held steady regardless of race or age, with no evidence that either factor introduced bias into its risk assessments. The findings support MMAI's reliability in addressing critical equity considerations for clinical adoption of AI-based biomarkers in prostate cancer care.

Artera will also be exhibiting at ASTRO2026 at Booth #2444, where attendees can learn more about the Artera platform.

About Artera

Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized histopathology images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe.

Artera’s FDA-authorized software products include ArteraAI Prostate (de novo authorization) and ArteraAI Breast (510(k) clearance). In addition, Artera has received CE Marking for its prostate and breast cancer in vitro diagnostic tests, supporting regulated availability in international markets.

Artera’s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.

Artera’s headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit artera.ai.